In the BioHarmony Drug Report Database

"Preview" Icon

Abemaciclib

Verzenio, Verzenios (abemaciclib) is a small molecule pharmaceutical. Abemaciclib was first approved as Verzenio on 2017-09-28. It has been approved in Europe to treat breast neoplasms. It is known to target cyclin-dependent kinase 6 and cyclin-dependent kinase 4. Verzenio’s patent is valid until 2029-12-15 (FDA).

 

Trade Name

 

Verzenios
 

Common Name

 

abemaciclib
 

ChEMBL ID

 

CHEMBL3301610
 

Indication

 

breast neoplasms
 

Drug Class

 

Cyclin dependent kinase inhibitors

Image (chem structure or protein)

Abemaciclib structure rendering